Q&A: New BIO chair to steer industry through ‘existential threats’ despite FDA receptivity

Max Bayer

Pharma Reporter

BOSTON — Fritz Bittenbender, the newly-named chair of BIO, is guiding the group through the kind of split-screen experience that has defined the first several …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

Q&A: New BIO chair to steer industry through ‘existential threats’ despite FDA receptivity

Max Bayer

Pharma Reporter

Sign up to read this article for free.

Gilead gets groundbreaking FDA approval for twice-yearly HIV prevention shot

How a tailored ALS drug could help broaden rare disease therapies

Grail shares jump on study results for cancer test

Zealand study shows higher GLP-1/GLP-2 doses may lead to greater weight loss

Scholar Rock’s muscle-preserving obesity drug add-on looks competitive

This company has spent a decade innovating NGS-based companion diagnostics worldwide–what’s next?

Q&A: New BIO chair to steer in­dus­try through ‘ex­is­ten­tial threats’ de­spite FDA re­cep­tiv­i­ty

Max Bayer

Pharma Reporter

Sign up to read this article for free.

Gilead gets ground­break­ing FDA ap­proval for twice-year­ly HIV pre­ven­tion shot

How a tai­lored ALS drug could help broad­en rare dis­ease ther­a­pies

Grail shares jump on study re­sults for can­cer test

Zealand study shows high­er GLP-1/GLP-2 dos­es may lead to greater weight loss

Schol­ar Rock’s mus­cle-pre­serv­ing obe­si­ty drug add-on looks com­pet­i­tive

This com­pa­ny has spent a decade in­no­vat­ing NGS-based com­pan­ion di­ag­nos­tics world­wide–what’s next?

Q&A: New BIO chair to steer industry through ‘existential threats’ despite FDA receptivity

Gilead gets groundbreaking FDA approval for twice-yearly HIV prevention shot

How a tailored ALS drug could help broaden rare disease therapies

Grail shares jump on study results for cancer test

Zealand study shows higher GLP-1/GLP-2 doses may lead to greater weight loss

Scholar Rock’s muscle-preserving obesity drug add-on looks competitive

This company has spent a decade innovating NGS-based companion diagnostics worldwide–what’s next?